Several studies reported that long-term use of antipsychotics may lead to a decrease in BMD and osteoporosis in relation to hyperprolactinemia [10–12] and currently, it is a generally accepted approach to categorize antipsychotics according to their effects on prolactin levels as prolactin-raising (PR) and prolactin-sparing (PS) antipsychotics [13–15]. The gene discussed is PRL; the disease is hyperprolactinemia.